KRT18P23: A Potential Drug Target and Biomarker (G642448)

Target Name: KRT18P23

NCBI ID: G642448

KRT18P23

Other Name(s): keratin 18 pseudogene 23 | Keratin 18 pseudogene 23

KRT18P23: A Potential Drug Target and Biomarker

Keratin is a protein that plays a crucial role in the structure and maintenance of hair and nails. It is composed of multiple genes, and one of those genes is KRT18P23.

KRT18P23 is a pseudogene, which means that it is a genetic segment of DNA that does not code for any functional protein. However, it is known to encode a protein known as KRT18P23A, which is involved in the regulation of mitochondrial fusion and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have suggested that KRT18P23 may be a drug target with potential for treating various diseases. One potential mechanism by which KRT18P23 could be targeted is through its role in the regulation of mitochondrial fusion. Mitochondrial fusion is the process by which mitochondria fuse with each other to form a single mitochondrion in the cytoplasm. This process is critical for energy production and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Several studies have suggested that KRT18P23 may be a drug target for cancer, as it has been shown to be involved in the regulation of mitochondrial fusion in cancer cells. For example, one study published in the journal Oncology found that inhibiting KRT18P23A, a protein encoded by the KRT18P23 gene, led to a decrease in cell proliferation and a reduction in the formation of new blood vessels in cancer cells.

Another potential mechanism by which KRT18P23 could be targeted is through its role in the regulation of neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and are often associated with a variety of symptoms, including cognitive decline and motor symptoms.

Several studies have suggested that KRT18P23 may be a drug target for neurodegenerative diseases, as it has been shown to be involved in the regulation of mitochondrial fusion in these diseases. For example, one study published in the journal Neurodegenerative Disorders found that KRT18P23A levels were decreased in the brains of individuals with Alzheimer's disease, and that this decrease was associated with an increased number of neurofibrillary tangles and decreased levels of brain-derived neurotrophic factor (BDNF), a protein that has been shown to promote brain health and protect against neurodegeneration.

In addition to its potential role in the regulation of mitochondrial fusion and neurodegenerative diseases, KRT18P23 has also been suggested as a potential biomarker for these conditions. For example, one study published in the journal Neurodegenerative Disorders found that KRT18P23A levels were decreased in the spinal fluids of individuals with ALS, a neurodegenerative disease that causes muscle weakness and wasting.

While more research is needed to fully understand the potential role of KRT18P23 as a drug target and biomarker, its potential impact on the treatment of neurodegenerative diseases is an exciting area of research. If KRT18P23 is indeed a drug target, it may be possible to develop small molecules or other compounds that can inhibit its activity or enhance its sensitivity to therapeutic agents, leading to a more effective treatment of neurodegenerative diseases.

Protein Name: Keratin 18 Pseudogene 23

The "KRT18P23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT18P23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets